Polscreen, a National Coronary Heart Disease Prevention Program, began. It was the largest global population-based study, developed by the Prevention Committee of the Polish Cardiac Society, financed by a research grant for Polpharma and awarded funds for the years 2002–2005.
The parent company of Polpharma Group is situated in the Netherlands:
Polpharma Group Holding B.V.
COC: Amsterdam nr. 96080892
© Polpharma Group Holding B.V. 2025. All rights reserved.
Herengracht 480, 1017 CB Amsterdam, The Netherlands
+31 (0)20 705 4800